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Riparin II (RipII), an alkamide isolated from the green fruit of Aniba riparia, was tested in the various ani-
mal models of inﬂammation to investigate its anti-inﬂammatory activity. Male Wistar rats (180–240 g)
were treated with RipII by gavage at doses 25 or 50 mg/kg, before initiating the inﬂammatory responses.
The tests used were paw edema induced by carrageenan, dextran, histamine or serotonin; peritonitis
induced by carrageenan and fMLP, as well as the measurement of MPO activity, TNF-a and Il-1b amount
in the peritoneal ﬂuid. In the animal models of carrageenan and dextran-induced paw edema, the animals
treated with RipII showed lower edema than those of the control group. Treatment with RipII also
reduced the paw edema induced by histamine but not serotonin. In the carrageenan-induced peritonitis
model, treatment with RipII reduced leukocyte migration, the MPO activity and the amount of TNF-a and
IL-1b in the peritoneal ﬂuid. In summary, these results indicate that RipII has an anti-inﬂammatory activ-
ity in chemical models of acute inﬂammation. RipII might be directly or indirectly inhibiting the activity,
production or release of pro-inﬂammatory mediators involved in the generation of the pain associated
with inﬂammation.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Over the years, natural products have contributed signiﬁcantly
to the discovery and development of important modern therapeu-
tic drugs [1–3].
Aniba riparia (Ness) Mez is a species belonging to the Lauraceae
family, and the genus Aniba is typical of the Amazon (Brazil), where
it is popularly known as ‘‘louro’’ [4]. Its fruits contain various
chemical constituents such as ﬂavonoids, neolignans, stirilpironas
and alkamides [5].
In earlier studies, the substances N-methyl benzoiltyramine
(riparin I), N-(2-hydroxybenzoyl)-tyramine (riparin II) and
N-(2,6-dihidroxibenzoil)-tyramine (riparin III) (Fig. 1), isolatedfrom the unripe fruit of A. riparia (Ness) Mez, have demonstrated
several biological activities, including antimicrobial and antimalar-
ial efﬁcacy [6–8].
These three alkamides have been shown to induce non-speciﬁc
and reversible relaxation of contractions produced by acetylcho-
line and histamine in guinea pig ileum and by oxytocin and brady-
kinin in the uterus of virgin rats [9]. This relaxing effect was
previously shown to be associated with the inhibition of the inﬂux
of calcium ions into the intracellular compartment and inhibition
of the release of intracellular calcium stores, without affecting cyc-
lic adenosine monophosphate (cAMP) generation [10].
Riparins contain tyramine, a sympathomimetic amine with an
indirect mode of action, in their chemical structure. For this reason,
studies conducted by our group have evaluated the effects from
these substances on the central nervous system. Data from these
studies showed that riparin I [11], riparin II [12] and riparin III
[13,14] exhibited anxiolytic-like effects in mice, while riparin II
[15] and riparin III [16] produced antidepressant effects. Riparin I
also demonstrated antinociceptive activity, which could involve
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and central mechanisms [17].Fig. 1. Structure of riparins.2. Materials and methods
2.1. Riparin II isolation, puriﬁcation and identiﬁcation
Barbosa-Filho et al., described the process of extraction of the
Riparin II (RipII) from A. riparia. A sample of RipII were deposited
in the Bank of Standards of Natural and Synthetic Products of the
Laboratório de Tecnologia Farmacêutica of the Universidade Fed-
eral da Paraíba, and to be used in this work, it was repuriﬁed by
Preparative Thin Layer Chromatography (PTLC) silica gel Merck
using the same system as described in the original paper. Spectro-
scopically pure RipII was conﬁrmed by Analytical Thin Layer Chro-
matography (TLC) and High-performance Liquid Chromatography
(HPLC). The identiﬁcation of the RipII was performed by analyzing
1H and 13C NMR spectral data compared with those published in
the original literature [18].
2.2. Animals
Male rats (180–240 g) and Male Swiss mice (27–32 g) were
used in this study. The animals were maintained on a 12/12 h
light/dark cycle, with access to water and food ad libitum, and
the experiments were performed at an ambient temperature of
26 ± 2 C. All experiments were performed in accordance with
the current guidelines for the care of laboratory animals and the
ethical guidelines for investigations of experimental pain in con-
scious animals [19]. The study was also performed under the con-
sent and surveillance of the Ethics Committee from the
Department of Physiology and Pharmacology of Federal University
of Ceará (Protocol number 40/10).
2.3. Drugs
RipII was emulsiﬁed with 3% Tween 80 (VETEC, USA) and
administered intragastric in male rats at single doses of 25 or
50 mg/kg. Control groups (vehicle) received the same volume of
3% Tween 80 as the treated groups dissolved in distilled water.
The following drugs were used: indomethacin, cyproheptadine,
dexamethasone, carrageenan, dextran, histamine, serotonin, and
N-formyl-methionyl-leucyl-phenylalanine (fMLP). All drugs were
purchased from Sigma Chem. Co (St. Louis, MO, USA). All drugs
were dissolved in saline solution immediately before use, with
the exception of indomethacin, which was dissolved in 8.4%
NaHCO3. The vehicles used alone had no effects per se on the
inﬂammatory responses in rats.
2.4. Experimental procedures
2.4.1. Paw edema induced by carrageenan
Rats were divided in four groups that received vehicle (3% of
Tween 80 with distilled water, by gavage), RipII (25 or 50 mg/kg,
by gavage) or indomethacin (10 mg/kg, by gavage). Sixty minutes
later, the animals received an intraplantar injection of 1% carra-
geenan (100 ll) to induce edema in the right hind paw. The volume
of the paws was measured before and 1, 2, 3, 4 and 24 h after the
administration of carrageenan [20].
The volume of the edema in milliliters was measured using a
Pletismometer (Ugo Basile, Italy), where the right hind paw was
submerged up to the tibio-tarsal joint, in the measuring chamber
of the device. The volume of ﬂuid displaced was recorded and
considered the volume of the paw. The results were expressed
as the difference between the volume of the paw at the speciﬁedtime intervals and the volume before the carrageenan injection
(t = 0).
2.4.2. Paw edema induced by dextran
Animals were divided in four groups and pre-treated with vehi-
cle (3% of Tween 80 with distilled water, by gavage), RipII (25 or
50 mg/kg, by gavage) or cyproheptadine (10 mg/kg, by gavage).
Sixty minutes later, the animals received an intraplantar injection
of dextran 1.5% (100 ll) to induce the edema in the right hind paw.
The volume of the paws was measured before and 1, 2, 3 and 4 h
after dextran administration [21].
The volume of the edema in milliliters was registered using a
Pletismometer (Ugo Basile, Italy), where the right hind paw was
submerged until the tibio-tarsal joint in the measuring chamber
of the device. The volume of ﬂuid displaced was recorded
and considered the volume of the paw. The results were ex-
pressed as the difference between the volume of the paw at
the referred time intervals and the volume before of the dextran
injection.
2.4.3. Paw edema induced by histamine and serotonin in rats
The experiments were performed in accordance with the meth-
odologies of earlier studies [22]. Rats were divided in three groups
and treated with vehicle (3% of Tween 80 with distilled water, by
gavage) or RipII (25 or 50 mg/kg, by gavage). Sixty minutes later,
the animals received an intraplantar injection of histamine
(200 lg/paw) or serotonins (200 lg/paw) induce edema in the
right hind paw. The volume of the paws was registered using a ple-
tismometer at several times after the injection of the inﬂammatory
stimulus. In the histamine-induced paw edema, the measurements
were taken before and after 15, 30, 60 and 90 min; in the seroto-
nin-induced paw edema, the measurements were taken before
and after 15, 30 and 60 min; and in the bradykinin-induced paw
edema, the measurements were taken before and after 15 and
30 min.
2.4.4. Carrageenan-induced leukocyte migration in the rat peritoneal
cavity (peritonitis)
The carrageenan solution (500 lg/ml) or sterile saline (0.9%, w/
v) was injected in the peritoneal cavities of rats (1 mL). Four hours
later, the rats were sacriﬁced, and the peritoneal cavity was
washed with 10 ml of saline containing heparin 5 IU/ml. The peri-
toneal ﬂuid was recovered for the analysis of leukocyte numbers
with a Neubauer chamber, IL-1b and TNF-a concentrations, and to-
tal protein [23] and for the quantiﬁcation of myeloperoxidase
(MPO) activity. The rats were treated orally with RipII (25 or
50 mg/kg), dexamethasone (5 mg/kg) or vehicle 1 h before receiv-
ing the i.p. injection of the carrageenan solution [24].
MPO activity, a marker for neutrophil inﬁltration, was quanti-
ﬁed in the peritoneal ﬂuid using an assay adapted from the method
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were vigorously mixed with 0.9 ml of 0.5% hexadecyltrimethylam-
monium bromide potassium phosphate buffer solution. Aliquots of
30 ll were transferred to 96-well plates. Hydrogen peroxide and
h-dianisidine were added to the samples. The reaction between
H2O2 and h-dianisidine, catalyzed primarily by MPO in the sam-
ples, generates a color solution that was measured spectrophoto-
metrically (absorbance at 460 nm) to provide an index of MPO
activity. The results are shown as MPO units per milliliter. IL-1b
and TNF-a were quantiﬁed in the peritoneal ﬂuid by enzyme-
linked immunosorbent assays (ELISA); Amersham TNF-a Rat
Biotrak ELISA System (assay range: 31–2500 pg/ml and sensitivity:
<15 pg/ml) and Amersham IL-1b Rat Biotrak ELISA (assay range:
25.6–2500 pg/ml and sensitivity: 12 pg/ml), according to the
instructions of the manufacturer.2.4.5. Leukocyte migration induced by bacterial chemotactic peptide
N-formyl-methionyl-leucyl-phenylalanine (fMLP) in the rat peritoneal
cavity (peritonitis)
A procedure similar to that used to produce carrageenan-
induced peritonitis was performed to evaluate the capacity of RipII
(25 or 50 mg/kg) to block the neutrophil migration in response to
fMLP, a direct stimulator of leukocytes. A solution of fMLP
(100 nmol) or sterile saline (0.9%, w/v) was injected (1 mL) in the
peritoneal cavities of the rats. Four hours later, the rats were
sacriﬁced and the peritoneal cavity was washed with 8 ml of saline
containing 5 IU/ml heparin. The peritoneal ﬂuid was recovered for
the analysis of leukocyte numbers with a Neubauer chamber [26].2.4.6. Measurement of membrane lipids peroxidation
The rate of lipoperoxidation in the paw was estimated by deter-
mination of malondialdehyde (MDA) using the thiobarbituric acid
reactive substances (TBARS) test. The paws were washed with
saline to eliminate the interference of hemoglobin with free radi-
cals. The paws were homogenized to 10% of tissue with potassium
phosphate buffer. Then 63 lL was removed and add 100 lL of 35%
perchloric acid, and the mixture was centrifuged at 14,000 rpm for
10 min at 4 C. The supernatant (approximatetly 150 lL) was re-
moved, mixed with 50 lL of 1.2% thiobarbituric acid and incubated
at 100 C for 30 min. After cooling, the absorbance at 532 nm was
measured. The results were expressed as nmol MDA/g tissue.2.4.7. Measurement of nitrite amount
The nitrite amount was determined by a colorimetric assay
similar to describe by Green et al. [27]. Brieﬂy, 50 lL of each
paw homogenate was mixed with the same volume of Griess
reagent. This reagent consist of equals parts of 5% phosphoric
acid, 1% sulfanilamide, 0.1% naphthyl ethylenediamine dihydro-
chloride (NEED) and distilled water. The absorbance was read
at 540 nm on microplate reads (UVM-340, Asys Hitech, Nether-
lands). The amount of nitrite was calculated from a NaNO2
standard curve. NO2 is a major unstable product of NO and
molecular oxygen reaction, and gives an indication of free radi-
cals generation.3. Statistical analyses
Graph Pad Prism 5.0 software was used for the statistical
analyses. The results are shown as the mean ± SEM. The statistical
signiﬁcance of difference between the groups was assessed by
one-way ANOVA, followed by the Student–Newman–Keuls post
hoc test. Values of p less than 0.05 were considered signiﬁcant.4. Results
4.1. Evaluation of the anti-inﬂammatory properties of RipII on rat paw
edema
The administration of RipII at both doses (25 and 50 mg/kg, p.o.)
signiﬁcantly reduced the carrageenan-induced paw edema two
hours after the administration of the stimulus compared to the ani-
mals pre-treated with vehicle. Indomethacin (10 mg/kg, p.o.), a
non-steroidal anti-inﬂammatory used as a drug of reference, signif-
icantly reduced the volume of paws at all periods observed com-
pared to the vehicle (Fig. 2A). RipII (25 or 50 mg/kg, p.o.) also
reduced the dextran-induced edema compared to the vehicle,
except in the third hour following dextran application. As ex-
pected, cyproheptadine (10 mg/kg, p.o.) was effective at all times
(Fig. 2B). Both doses of RipII signiﬁcantly reduced the histamine-
induced paw edema (Fig. 2C) but were not able to reduce the vol-
ume of the edema induced by serotonin compared to the vehicle
group (Fig. 2D) at any time.
4.2. Evaluation of the anti-inﬂammatory properties of RipII in
carrageenan or fMLP-induced peritonitis
Administration of carrageenan increased the total number of
leukocytes in the peritoneal ﬂuid. Pretreatment with RipII at doses
of 25 or 50 mg/kg (p.o.) signiﬁcantly reduced the numbers of leu-
kocytes, corresponding to an inhibition of 23.58% and 39.92%,
respectively. Dexamethasone (5 mg/kg, p.o.), used as reference
drug, diminished the cellular inﬁltrate by 81.80% relative to the
vehicle-treated group (Fig. 3A). Intraperitoneal administration of
fMLP resulted in a strong migration of leukocytes into the perito-
neal cavity compared to the group treated only with saline. The
pretreatment with RipII (25 and 50 mg/kg, p.o.) signiﬁcantly re-
duced the cell migration, corresponding to inhibitions of 26.21%
and 22.52%, respectively. As expected, dexamethasone (5 mg/kg,
p.o.) was able to suppress leukocyte recruitment by 49.18%
(Fig. 3B). RipII, at both doses, signiﬁcantly reduced the protein
concentration in the peritoneal ﬂuid compared to the vehicle, cor-
responding to an inhibition of 41.6% and 40.36%, respectively,
while dexamethasone reduced this parameter by 61.92%
(Fig. 3C). The intraperitoneal injection of carrageenan solution
(500 lg/cavity) induced an increase in MPO activity, an indirect
evaluation of the accumulation of neutrophils, compared to the
values obtained from the animals treated with saline. RipII (25 or
50 mg/kg, p.o.) and dexamethasone signiﬁcantly reduced the activ-
ity of MPO when compared to the vehicle (by 49.95%, 26.44% and
53.05%, respectively) (Fig. 3D). RipII at both doses tested, as well
as dexamethasone, also decreased the concentration of TNF-a to
38.54%, 66.7% and 48.46%, respectively, of the values obtained for
the vehicle-treated animals (Fig. 4B). RipII at 25 mg/kg and dexa-
methasone reduced the amount of IL-1b to 41.8% and 62.3%,
respectively, of that of the vehicle-treated group (Fig. 4A).
4.3. Effect of RipII on the membrane lipid peroxidation marker – MDA
Administration of carrageenan increased the MDA amount in
the paws. The treatment with RipII in the both doses decreased
the MDA amount, a reduction of 59.02% and 59.94%, respectively.
Indomethacin, used as reference drug, diminished the parameter
by 52.36% compared to the vehicle-treated group (Fig. 5A).
4.4. Effect of RipII on the nitrite amount
The quantity of nitrite was increased in the paws of animals
treated only with vehicle. The pretreatment with RipII in the both
Fig. 2. Time course of the effect of RipII treatment on paw oedemas induced by carrageenan (1%) (A), dextran (0.15%) (B), serotonin (200 lg/paw) (C) or histamine (200 lg/
paw) (D) in rat. Animals were pre-treated with RipII (25 or 50 mg/kg, intragastrically), indomethacin (10 mg/kg, i.p.), ciproheptadine (5 mg/kg, i.p.) or vehicle, before receiving
intraplantar injections of the inﬂammatory agents. The oedema was measured with a plethysmometer at each time point marked. Each point represents the mean ± SEM.
#p < 0.05 RipII-25, RipII-50, Indomethacin and ciproheptadine vs. vehicle, ⁄p < 0.05 vs. vehicle; Dp < 0.05 RipII-25, RipII-50 vs. vehicle (ANOVA and Student–Newman–Keuls
post hoc test).
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reduction of 45.99% and 47.44%, respectively (Fig. 5B).
5. Discussion
Injection of carrageenan into the hind paw of an animal pro-
duces the cardinal signs of inﬂammation: edema, erythema (rubor
or redness) and hyperalgesia (increased sensitivity to painful stim-
uli). These signs develop rapidly due to the activity of many pro-
inﬂammatory mediators derived from plasma or cells involved in
the inﬂammatory response [28].
The present results demonstrate that RipII reduced the carra-
geenan-induced paw edema. This effect was observed 2 and 24 h
after carrageenan administration, suggesting that the mechanism
of action of RipII might involve suppression of the inﬂammatory
process induced by this agent. After the carrageenan injections,
there is a characteristic sequence of release of inﬂammatory medi-
ators. The initial edematous phase primarily involves histamine,
serotonin and bradykinin. This phase is followed by an increase
of prostaglandins in the damaged tissue. The prostaglandin in-crease coincides with the migration of leukocytes, which can am-
plify the inﬂammatory response through the production of other
inﬂammatory mediators, reactive oxygen species (ROS), and in-
creases myeloperoxidase activity and production of NO [29–32].
Edema induced by intraplantar injection of dextran proceeds
through a different mechanism from that evoked by carrageenan.
Dextran induces edema without the involvement of polymorpho-
nuclear leukocytes in the inﬂamed tissue. Instead, mast cell activa-
tion and degranulation result in the release of high concentrations
of biologically active amines, such as histamine and serotonin [33].
In the present work, RipII decreased the dextran-induced edema
formation in the mouse paws, suggesting that the RipII effects
could involve blocking the histamine and/or serotonin receptors
or inhibition of their release from mast cells. Effects on histamine
are more likely than effects on serotonin, as the direct effect of
serotonin was not prevented by RipII treatment.
Thus, RipII appears to have the capacity to suppress the edemas
induced by direct injection of histamine, a vasoactive amine that
plays a fundamental role at inﬂammatory process by increasing
of cell permeability, expansion of venules, increased ﬂuid secretion
Fig. 3. Effect of RipII at 25 and 50 mg/kg doses and dexamethasone at 5 mg/kg p.o. on total leukocyte count in animals with peritonitis induced by carrageenan (A), or fMLP
(B); protein concentration (C) and myeloperoxidase activity (D) were measured in the peritoneal ﬂuid of animals with carrageenan-induced peritonitis. Results are presented
as mean ± SEM. ⁄⁄⁄p < 0.001, ⁄⁄p < 0.01, ⁄p < 0.05 vs. vehicle (ANOVA and Student–Newman–Keuls post hoc test). Peritoneal ﬂuids of animal without peritonitis are shown as
healthy.
Fig. 4. Effect of RipII at 25 and 50 mg/kg doses and dexamethasone at 5 mg/kg p.o. on TNF-a and IL-1b in the peritoneal ﬂuid of animals with carrageenan-induced peritonitis.
Results are presented as mean ± SEM. ⁄⁄⁄p < 0.001, ⁄⁄p < 0.01, ⁄p < 0.05 vs. vehicle (ANOVA and Student–Newman–Keuls post hoc test). Peritoneal ﬂuids of animal without
peritonitis are shown as healthy.
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migration may explain the anti-inﬂammatory proﬁle of RipII in the
carrageenan-induced paw edema [34–37].
In addition to histamine and serotonin, bradykinin is also pres-
ent in the initial phase of carrageenan-induced edema. Some previ-
ous studies have demonstrated that administration of bradykinin
causes a long-lasting inﬂammatory reaction, mainly mediated by
B2 receptors. This inﬂammatory action is modulated, at least in
part, by the activation of PKC (Protein kinase C) and later by sensi-
tization of the TRPV1 (transient receptor potential vanilloid 1),
which facilitates the release of other pro-inﬂammatory mediatorsby promoting the entry of calcium into cells [38,39]. Thus, we
can hypothesize that RipII may have the capacity to decrease the
nociceptive effect of TRPV1 agonists (data not published). This
would suppress the mobilization of arachidonic acid, the precursor
to prostaglandins and leukotrienes.
Taken together, the ability of RipII to reduce the edema forma-
tion induced by carrageenan, dextran and histamine suggests a
high potential of this substance to intervene in the initial establish-
ment of acute inﬂammatory process.
In the acute inﬂammatory process, there are two main changes:
cellular and vascular events. The inﬁltration of leukocytes is one of
Fig. 5. Effect of RipII 25 and 50 mg/kg on lipoperoxidation level-content of MDA (A) and nitrite content (B) in the paws. One additional group received vehicle and was not
exposed to carrageenan (health). Results are presented as mean ± SEM. ⁄⁄⁄p < 0.001, ⁄⁄p < 0.01, ⁄p < 0.05 vs. vehicle (ANOVA and Student–Newman–Keuls post hoc test).
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event, while the increased vascular permeability with exudation or
transudation constitutes a vascular event [40–43].
In this work, we evaluated the effect of RipII at doses of 25 and
50 mg/kg in the inﬂammatory model of carrageenan-induced peri-
tonitis, which causes leukocyte migration to the peritoneal cavity
of rats. Pre-treatment with RipII at both doses decreased leukocyte
migration, protein concentration and MPO activity in the perito-
neal ﬂuid of the rats with peritonitis. The lower protein content
in these rats demonstrates the ability of RipII to decrease vascular
permeability and also supports the results obtained in the edema
models.
Cytokines serve as messengers between cells in many physio-
logical and pathological processes [44]. IL-1b causes both dose-
and time-dependent neutrophil migration in various models and
animal species [45]. This cytokine might act directly on the target
cells or through the induction and secretion of eicosanoids and
chemokines [46]. TNF-a, another pro-inﬂammatory cytokine, is re-
leased primarily by activated macrophages and has a fundamental
role in many conditions, including inﬂammation, immune-modu-
lation, cytotoxicity and apoptosis [47,48].
In this study, we showed the ability of RipII to decrease TNFa
and IL-1b in the peritoneal ﬂuid of rats with carrageenan-induced
peritonitis. TNFa is one of the agents initially released in response
to carrageenan and is a cytokine marker of acute inﬂammation.
Thus, the observed results corroborate our edema measurements
and leukocyte counts, clarifying, at least in part, the mechanism
of the anti-inﬂammatory activity of RipII.
Carrageenan is a ﬂogistic agent that induces the migration of
leukocytes by an indirect mechanism [49], unlike fMLP, which is
a peptide with a recognized direct chemotactic activity on the neu-
trophils [50].
Our results showed that administration of fMLP induces a sub-
stantial cell inﬁltrate and that pretreatment with RipII decreased
the number of leukocytes in the peritoneum compared to the con-
trol group, similarly to dexamethasone. This observation indicates
that RipII diminishes leukocyte migration by an indirect mecha-
nism, probably reﬂecting its ability to reduce the inﬂammatory
processes including release of TNFa and IL-1b. RipII would thus
partially suppress the effects of these mediators on leukocytes
and endothelial cells. We do not understand the mechanism be-
hind of the capacity to RipII decrease the IL-1b only in the lower
dose, but without any doubt the RipII is able to reduce the interleu-
kin release and the decreasing in TNFa per is capable to explain at
least in part the action of RipII as anti-inﬂammatory substance In
addition, RipII may directly prevent leukocyte stimulation by fMLP.
This tripeptide leads to leukocyte chemotaxis, adhesion, phagocy-
tosis and the release of superoxide anions by activation of formyl
peptide receptors, which are pertussis toxin-sensitive G-proteincoupled receptors [51,52]. Thus, the ability of RipII to reduce the
neutrophil inﬂux directly induced by fMLP could be due to antag-
onism of fMLP receptors or interference with their signaling.
In the assessment of the reduction of vascular permeability by
RipII, it was shown that RipII at both doses signiﬁcantly reduced
the concentration of protein, compared to the control group, simi-
lar to the effects of dexamethasone, conﬁrming its anti-inﬂamma-
tory activity. This result demonstrates the potential of RipII to
inﬂuence the inﬂammatory process both in cellular and vascular
events. The effects of RipII on histamine-induced paw oedema sug-
gest that this agent may inhibit histamine-activated processes.
Free radicals and related reactive species are strongly involved
in several pathologic and physiologic processes, including cancer,
cell death, inﬂammation, and pain. [53]. Thus, we assessed the
antioxidant potential of RipII by testing its ability to prevent oxida-
tive damage to lipids induced by a free-radical source. Vast evi-
dence has recently implicated that intracellular ROS production
plays a key role in modulation of release of other mediators of
inﬂammation. This is related mainly to the constitutive expression
of NAD(P)H oxidases (termed NOXs- non-phagocytic oxidases) in
various tissues [54,55]. ROS produced by this family of enzymes
can regulate adhesion molecule expression on endothelium and
inﬂammatory cells, thus affecting cell recruitment to the sites of
inﬂammation [56,57].
An indicative method, extensively used, of evaluating lipid per-
oxidation is analysis of tissue thiobarbituric acid reactive sub-
stance (TBARS). The reaction of malondialdehyde (MDA) with
thiobarbituric acid (TBA) to form a colored complex (TBA-MDA)
that can be quantiﬁed spectrophotometrically from its visible
absorbance (Em,x 532 nm) is the basis of the commonest method
used to assess lipid peroxidation in biological materials [58]. The
elevated levels of TBARS were signiﬁcantly decreased after the
treatment of RipII. This substance may protect the formation of
free radicals, which might reduce the inﬂammation.
We next investigated the antioxidant potential of RipII against
levels of nitrate. Nitric oxide (NO) and reactive oxygen species ex-
ert multiple modulating effects on inﬂammation and play a key
role in the regulation of immune responses. They affect virtually
every step of the development of inﬂammation. NO has been
shown to increase the production of pro-inﬂammatory prostaglan-
dins in in vitro [59–61], ex vivo [62] and in vivo studies [63,64],
potentially by S-nitrosation of cysteine residues in the catalytic do-
main of cyclo-oxygenase (COX) enzymes [65,66]. The RipII was
able to reduce the levels of nitrate.
In addition, the antioxidant action of RipII observed in the
TBARS and NO assays suggests that this substance may protect
against oxidative damage to membrane polyunsaturated fatty
acids, such as arachidonic acid, which is a very important compo-
nent in the response to pain the cyclooxygenase pathway.
A.M.R. de Carvalho et al. / Chemico-Biological Interactions 205 (2013) 165–172 171In conclusion, RipII, a substance isolated from the green fruit of
A. riparia, is a molecule with interesting anti-inﬂammatory activity
potentially due its ability to decrease TNF-a and IL-1b production
and its histamine antagonism. Furthermore, the inhibition of
migration of polymorphonuclear neutrophils implicated in the
inﬂammatory process may also play a role in its biologic activities.
Given the increased interest in obtaining natural products with
therapeutic potential, RipII should be further examined and possi-
bly used to produce drugs for the treatment of inﬂammatory
diseases.6. Conﬂict of interest
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